Low serum interleukin-13 levels correlate with poorer prognoses for colorectal cancer patients.
Interleukin-13 (IL-13) is an immunosuppressive cytokine produced by several immune cells and cancer cells. The aim of this retrospective study was to determine if serum IL-13 levels have an association with clinical outcome in patients with colorectal cancer. A total of 241 patients with colorectal cancer were enrolled in the present study. Preoperative serum IL-13 concentrations were measured by enzyme-linked immunosorbent assay. We analyzed the association of serum IL-13 levels with clinicopathological variables. Patients with lymph node metastasis, lymphatic invasion, vascular invasion, distant metastases or advanced stage of disease had significantly lower serum IL-13 levels. Low serum IL-13 was significantly associated with both poor recurrence-free and overall survival. Multivariate analysis showed that low IL-13 levels were an independent predictive marker for poor prognosis. In conclusion, our data suggest that low serum IL-13 levels may be a useful predictive marker for poor prognosis in colorectal cancer.
Department of Gastrointestinal and Pediatric Surgery, Mie University Graduate School of Medicine, Mie, Japan.
Susumu
S
Saigusa
Koji
K
Tanaka
Yasuhiro
Y
Inoue
Yuji
Y
Toiyama
Yoshinaga
Y
Okugawa
Takashi
T
Iwata
Yasuhiko
Y
Mohri
Masato
M
Kusunoki
D014408:Biomarkers, Tumor / Q000097:blood*; D015179:Colorectal Neoplasms / Q000097:blood* / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D018793:Interleukin-13 / Q000097:blood*; D011237:Predictive Value of Tests; D011379:Prognosis; D012189:Retrospective Studies
D014408:Biomarkers, Tumor; D018793:Interleukin-13
Colorectal cancer; Prognosis; Recurrence; Serum IL-13